Locus in Pre-B Cells
Department of Immunology, Duke University Medical Center, Box 3010, 328 Jones Building, Research Drive, Durham, North Carolina 27710,1 Department of Molecular and Cell Biology, University of California, 439 Life Sciences Addition, Berkeley, California 947202
Received 18 July 2005/ Returned for modification 15 September 2005/ Accepted 11 November 2005
| ABSTRACT |
|---|
|
|
|---|
) locus is regulated in a lineage- and stage-specific manner during B-cell development. The highly restricted timing of V to J gene recombination at the pre-B-cell stage is under the control of two enhancers, the intronic enhancer (
Ei) and the 3' enhancer (
E3'), flanking the constant exon. E2A transcription factors have been indicated to be directly involved in the regulation of Ig
locus activation. In this study, we utilize E2A-deficient pre-B cells to directly investigate the mechanism of E2A-mediated Ig
activation. We demonstrate that Ig
germ line transcription is severely impaired and recombination is blocked in the absence of E2A. Reconstitution of E2A/ pre-B cells with inducible human E2A (E47R) is sufficient to promote chromatin modification of Ig
and rescue Ig
germ line transcription and J
gene recombinase accessibility. Furthermore, we show that increased E2A recruitment to
Ei and
E3' correlates with activation of Ig
in pre-B cells and that recruitment of E2A to
E3' is in part dependent on the transcription factor IRF-4. Inhibition of IRF-4 expression in pre-B cells leads to a significant reduction of Ig
germ line transcription and enhancer acetylation. In the absence of E2A, increased IRF-4 expression is not sufficient to promote Ig
enhancer chromatin modification or transcription, suggesting that the sequential involvement of IRF-4 and E2A is necessary for the activation of the Ig
locus. Finally, we provide genetic evidence in the mouse that E2A gene dosage can influence the development of pre-B cells during the phase of Ig
gene activation. | INTRODUCTION |
|---|
|
|
|---|
and
, that can potentially undergo recombination to generate a functional light chain gene. However, nearly all mature B cells express only one functional
or
light chain expressed from a single allele. It has been demonstrated with mice that the
genes are activated and undergo recombination before
, which contributes significantly to the preferential usage of the
light chain in mature B cells (95% of mature B cells in mouse are
+) (1, 28). Ig
light chain locus activation is mediated by cis-acting regulatory elements which include two enhancers, the intronic enhancer (
Ei) and the 3' enhancer (
E3'), located in the J-C intron and 3' of the C
exon, respectively. Deletion of either
Ei or
E3' negatively impacts the frequency of
recombination, resulting in a reduction in the ratio of
- versus
-expressing B cells, while deletion of both enhancers blocks
recombination altogether (13). Therefore, there is a degree of functional overlap between
Ei and
E3'. In addition, each
enhancer also mediates enhancer-specific, nonredundant effects which are required for normal
recombination and expression (8, 13, 35). The activation of Ig
locus recombination in pre-B cells correlates with the expression of sterile germ line transcripts that originate from an initiation site immediately 5' of the J
1 exon and from a second promoter approximately 3 kb 5' of J
1 (31, 34). Deletion of the region 5' of J
1 that contains the germ line transcript initiation sites severely impairs Ig
recombination in cis, indicating that germ line transcription may be involved in regulating recombinase accessibility of J
genes (4).
Kappa locus activation in pre-B cells is regulated by lineage-specific and ubiquitously expressed trans-acting factors. Molecular studies have implicated multiple transcription factors, such as E2A, NF-
B, Pax-5, Pu.1, SpiB, and IRF-4, in the regulation of Ig
locus activation (30). Strong evidence indicating that the ubiquitously expressed basic helix-loop-helix transcription factor E2A plays an important role in the regulation of Ig
has accumulated. Ectopic expression of E2A and the RAG recombinases in a nonlymphoid cell line is sufficient to induce a diverse repertoire of Ig
recombination (29). These data indicate that E2A expression is sufficient to promote chromatin modification and recombinase accessibility of the
locus. E2A DNA binding sites (E-boxes) have been identified within both
Ei and
E3', and chromatin immunoprecipitation (ChIP) studies confirm that E2A directly associates with these two enhancers in pre-B cells (10, 21, 25). Moreover, mutation of just one of two critical E-boxes, E1 or E2, in
Ei is sufficient to impair
recombination on the targeted allele in pre-B cells, while mutation of both sites results in an even more severe block in
recombination, thus directly demonstrating the functional importance of E2A in the regulation of Ig
(14). While these studies demonstrate the central importance of E2A in regulating Ig
transcription and recombination during B-cell development, it is not clear how E2A activity is regulated to ensure the proper timing of
locus activation and recombination.
E2A expression is upregulated upon B-cell lineage commitment and is highly expressed in both pro-B and pre-B cells (36). Additionally, it has been shown that E-boxes in
Ei and
E3' are already occupied in pro-B cells (33). Thus, it is likely that additional regulators are required to modulate E2A activity at Ig
in order to promote the proper timing of Ig
gene recombination during B-cell development. Interferon regulatory factor (IRF)-4 and related gene family member IRF-8 are required for the pro-B-cell-to-pre-B-cell transition and Ig
locus activation (17). IRF-4, also known as Pip or NF-EM5, was originally characterized as a factor recruited by the transcription factor Pu.1 to a composite DNA binding site found in
E3' and the Ig
enhancers E
2-4 and E
3-1 (6, 26). The ability of IRF-4 to bind to the composite site is dependent on Pu.1 and requires Pu.1 for transcriptional activity at
E3' (6). However, recent studies show that Pu.1 and the related Ets family transcription factor SpiB are not required for the induction of Ig
germ line transcription, suggesting that IRF-4 may regulate Ig
through another mechanism in pre-B cells (32). It has been shown that IRF-4 can cooperatively interact with E2A at
E3', resulting in enhanced E2A DNA binding and strong E2A/IRF-4 transcriptional synergy (22, 23). Additionally, IRF-4 expression increases as pro-B cells transition into pre-B cells in the bone marrow and in Ab-MuLV-transformed pre-B cells treated with the v-Abl inhibitor STI-571 (20). These studies indicate that the interaction of IRF-4 with E2A may play a central role in the regulation of the Ig
locus and suggest that IRF-4 may be a likely candidate regulator of E2A activity at
E3'.
We previously developed E2A-deficient pre-B-cell lines to study E2A-dependent gene regulation in B cells (9). In this study, we use these cell lines to directly investigate the causal links between E2A and Ig
activation and recombination. We show that E2A expression is required for Ig
germ line transcription and recombination and that retroviral expression of inducible human E2A cDNA in E2A/ pre-B cells can promote histone acetylation at the Ig
enhancers and germ line promoters. Chromatin immunoprecipitation assays revealed that E2A is recruited to the Ig
enhancers in a manner that correlates with the induction of
germ line transcription. We found that knockdown of IRF-4 transcript impaired E2A recruitment to
E3' and severely impaired
germ line transcription and enhancer histone acetylation. These data reveal that proper activation of the
locus in pre-B cells is in part dependent on IRF-4-mediated recruitment of E2A to
E3' and support the hypothesis that a synergistic interaction between these two factors plays an important role in regulating
E3' function in B lymphocytes.
| MATERIALS AND METHODS |
|---|
|
|
|---|
o-GFP mice have been described previously (15, 37). The E2A-deficient pre-B-cell lines were derived from Abelson murine leukemia virus (Ab-MuLV)-transformed bone marrow of a single E2AloxP/loxP mouse (24). Stable E2A/ cell lines were established by transduction with the MSCV-puro (Stratagene) retrovirus expressing Cre recombinase as previously described (9). Ab-MuLV pre-B cells transduced with MSCV-puro containing antisense Cre served as the wild-type control for the E2A/ cell lines. Clonal populations of E2A-deficient pre-B cells were derived from the Cre-transduced cells after puromycin selection. Human E47 estrogen receptor fusion protein reconstituted pre-B cells (E47R) were derived by transducing E2A/ pre-B-cell lines with the MIGR1-E47R retrovirus (9). IRF-4 knockdown pre-B-cell lines were derived by introducing one of two independent mouse expression arrest short hairpin RNA interference (shRNAi) constructs (Open Biosystems) into a wild-type Abelson virus-transformed pre-B-cell line by retroviral transduction. IRF-4 mRNA knockdown was verified by reverse transcriptase PCR (RT-PCR) after puromycin selection. All cell lines were maintained at 37°C in RPMI 1640 media (Gibco) supplemented with 10% heat-inactivated fetal bovine serum (HyClone), 100 U/ml penicillin (Gibco), 100 µg/ml streptomycin (Gibco), and 50 µM 2-mercaptoethanol (J. T. Baker). STI-571 and tamoxifen preparation. STI-571 (Gleevec; Novartis) was prepared as a 10-mM stock solution (1,000x) in water containing 10 mM HCl, sterile filtered, and stored in aliquots at 20°C until use. Tamoxifen (Sigma) was prepared as a 1-mM stock solution (1,000x) in cell-culture-grade dimethyl sulfoxide (DMSO) (Sigma) and stored at 20°C until use.
Gene expression analysis.
Total RNA was isolated from cells by use of TRIzol (Invitrogen) followed by isopropanol precipitation. Purified RNA was treated with RNase-free DNase I (Sigma), and random primed cDNA was made using Moloney murine leukemia virus reverse transcriptase (Invitrogen). Quantitative RT-PCR was performed with a Roche LightCycler and a FastStart DNA master SYBR green I kit (Roche). Semiquantitative RT-PCR was performed on serial dilutions of cDNA. Primers for RT-PCR are as follows: for E2A, E7 (CTAGCCCCTCAACGCCTGTG) and E15 (CGGTGCCAACAGCGTGGCT); for Ig
constant exon, AL2 (GATGTCTTGTGAGTGGCCCTC) and AL3 (CCAAAGACATCAATGTCAAGTGGAAG); for Ig
germ line transcript, IgK-GL 5' (GAGGGGGTTAAGCTTTCGCCTACCCAC) and IgK-GL 3' (CTGTATCTTTGCCTTGGAGAGTGCCAGAATCTGG); for IRF-4, IRF4#3 (GGCTTCACAATCTTCAAGGTGGAC) and IRF4#4 (CACACTTTCCTGTCGGGCTTAGAC); for SpiB, SpiB for (CTTCCAGTTCTCCTCCAAGCACAAG) and SpiB rev (TGGTAGGTGAGTTTGCGTTTGACC); for Spi1/PU.1, PU.1 for (CCTTATCAAACCTTGTCCCCAGCC) and PU.1 rev (ACCTCGCCTGTCTTGCCGTAGTTG); for RelA, relA for (GCAAGCCATTAGCCAGCGAATC) and relA rev (TTGAGAAAAGGAGCCTCGTGCC); for Pax-5, Pax-5a (CCGCCAAAGGATAGTGGAACTTG) and Pax-5b (CACAGTGTCATTGTCACAGACTCGC); for RAG1, YZ215 (TGCAGACATTCTAGCACTCTGG) and YZ216 (ACATCTGCCTTCACGTCGAT); for RAG2, YZ247 (CAGTGGGTCATAACATAGCC) and YZ248 (CTGGGTTCAGGGACATCTCC); and for EF1
, YZ95 (AGTTTGAGAAGGAGGCTGCT) and YZ96 (CAACAATCAGGACAGCACAGTC).
LM-PCR assay for RAG-mediated double-strand break.
Ligation-mediated PCR (LM-PCR) assays were conducted as previously described (20). Briefly, genomic DNA was prepared from cells and 1 µg of DNA was ligated overnight at 16°C with the BW linker. Signal ends were amplified by touchdown PCR using the linker-specific primer BW-1H and the J
-specific primer IgK-GL 5'. Touchdown PCR consisted of 30-s denaturation at 95°C; 30-s annealing at 68°C for 5 cycles, 65°C for 5 cycles, 62°C for 5 cycles, and 60°C for 20 cycles; and 45-s extension at 72°C. Specific PCR product was visualized by Southern blotting with the oligonucleotide probe Jk1-Jk2 (TGCTCTGTTCCTCTTCAGTG).
Mononucleosome chromatin immunoprecipitation assays.
Preparation of mononucleosomes and immunoprecipitations (IP) with antisera against acetyl-H3 and acetyl-H4 modified histones (Upstate Biotechnology) were performed as previously described (19). Briefly, nuclei were purified from Ab-MuLV-transformed pre-B cells and chromatin was partially digested with micrococcal nuclease (Worthington). Mononucleosomes were purified on a sucrose gradient, and immunoprecipitations were performed with antiserum against acetyl-H3 or acetyl-H4 modified histones. Normal rabbit serum was used as a negative IP control (Upstate Biotechnology). Quantitative PCR analysis of input and immunoprecipitated H3, H4, and control chromatin was performed using a Roche LightCycler and a FastStart DNA master SYBR green I kit (Roche). The primers used in this assay are as follows: for the intronic enhancer, IgKIE#2a (CTCTTGAAACTACTTTAGAGTCATTAAG) and IgKIE#2b (GAGTTCTTTACCAAGAAAAACAATAG); for the 3' enhancer, IgK3E#3a (TGATCAAGAAGACCCTTTTGAGGAAC) and IgK3E#3b (GGTAGGGAGCAGGTGTATGAGGCTT); for the
o promoter, IgKGL#1a (CCACCTTCTTCCTCAATGATC) and IgKGL#1b (CTGACATATTGTGCTTGGTTG); for the J
1 promoter, IgKGLs#1a (GAGGCTGTCAGATTCCTTGCAG) and IgKGLs#1b (GGGCTGGAGAGGTGGCTCAG); for glucose-6-phosphate dehydrogenase (G6PD), G6PD#1 (GGGTCAGCTCAGTCAAAGCACA) and G6PD#2 (TAGTTGCCGCTGCCAAACAC); and for 3' of the trypsinogen 4 gene (T4D), T4D#1 (GCCAGTACCTCTTAGACAA) and T4D#2 (GGGAGAGTAGAATTGTGTTA). All PCRs were performed in triplicate. The acetylation status of each site was determined by the IP bound signal/input signal. Each cell line was analyzed by at least two independent IP to confirm reproducibility. G6PD and T4D were used as positive and negative controls, respectively.
Immunoprecipitation of dual-affinity-tagged E2A.
Chromatin preparation and immunoprecipitation of dual-affinity-tagged E2A/DNA complexes were preformed as previously described (9). Enrichment of chromatin-immunoprecipitated DNA fragments was determined by quantitative PCR analysis using a Roche LightCycler and a FastStart DNA master SYBR green I kit (Roche), and the data are presented as ratio of immunoprecipitated DNA over input DNA. The PCR primers are as follows (Ig
intronic and 3' enhancer primers are the same as those used for the mononucleosome ChIP assay): for the Ig heavy chain Eµ, Eu for (TCAGAACCAGAACACCTGCAGCA) and Eu rev (GGTGGGGCTGGACAGAGTGTTTC); for the mb-1 promoter, mb-1 for (CCACGCACTAGAGAGAGACTCAA) and mb-1 rev (CCGCCTCACTTCCTGTTCAGCCG); and for the CD19 promoter, CD19 for (CCTAATGCTATCCCCAGATGATA) and CD19 rev (TAAATATTTTTCAGATGAGTGGG).
Flow cytometry. Bone marrow was prepared in fluorescence-activated cell sorter (FACS) buffer (1x phosphate-buffered saline, pH 7.4, plus 5% bovine calf serum) and stained on ice with CD43 phycoerythrin-, IgM biotin-, and B220 allophycocyanin-conjugated antibodies (BD Pharmingen), followed by streptavidin-Cy5-phycoerythrin staining (BD Pharmingen). Cells were run on a FACSCalibur and analyzed with CellQuest software (Beckman Coulter). Three hundred thousand events were collected for each sample, and dead cells were excluded by forward and side scatter gating.
| RESULTS |
|---|
|
|
|---|
5 (data not shown). These observations demonstrate that the loss of E2A at the pre-B-cell stage does not alter B-cell lineage identity or abolish the expression of select pre-B-cell-specific genes. Ab-MuLV pre-B cells can be induced to differentiate and initiate immunoglobulin light chain recombination (20, 31). Therefore, we sought to directly investigate the role that E2A plays in the regulation of immunoglobulin light chain gene expression and recombination with our E2A/ pre-B-cell lines.
It has previously been shown that recombinase accessibility of the
locus correlates with germ line transcription that originates from two promoters located 5' of the J
1 exon (31) (Fig. 1A). We first assayed immunoglobulin kappa light chain gene transcription by RT-PCR in E2A/ pre-B cells by using primers specific for the
constant exon. We found that the loss of Ig
transcript correlated with the loss of E2A expression in three independently derived clonal E2A/ pre-B-cell populations (Fig. 1B). Next, we asked if immunoglobulin light chain recombination was dependent on E2A. Previous studies have shown that Ab-MuLV pre-B cells can be induced to rearrange their immunoglobulin light chain genes by treatment with lipopolysaccharide (LPS) or the small molecule inhibitor of v-Abl, STI-571 (20). Wild-type and E2A/ pre-B cells were treated with LPS or STI-571, and light chain recombination was measured by LM-PCR. The accumulation of J
1 and J
signal ends (Fig. 1C) and coding joints (data not shown) could be readily detected in E2A sufficient pre-B cells treated with STI-571 but not in E2A/ pre-B cells. These results demonstrate that Ig light chain recombination is impaired in the absence of E2A.
|
regulation. Consistent with previous findings (20), STI-571-treated E2A+/+ pre-B cells showed accumulation of
germ line transcript as well as IRF-4, SpiB, RAG1, and RAG2 transcripts (Fig. 1D). However,
germ line transcript was undetectable in untreated E2A/ pre-B cells and was weakly induced by STI-571 in the absence of E2A. We did not observe a reduction in IRF-4, Pax-5, RelA, RAG1, or RAG2 transcript levels between the STI-571-treated E2A+/+ and E2A/ cells. Transcript levels of SpiB and PU.1 were each approximately two- to threefold lower in STI-571-treated E2A/ pre-B than levels in wild-type cells. These results show that the loss of E2A perturbs
germ line transcription but not the expression of genes known to be involved in immunoglobulin kappa transcription and recombination.
Human E47 rescues Ig
germ line transcription and recombination in E2A/ pre-B cells.
The correlation between E2A deficiency and defective Ig
germ line transcription suggests that E2A may play a direct role in regulating the activation state of Ig
genes. We further investigated the potential of E2A to activate Ig
by examining germ line transcription and recombination in E2A/ pre-B cells reconstituted with tamoxifen-inducible human E47 cDNA (E47R). We have previously shown that in the absence of tamoxifen E47R-reconstituted pre-B cells show no detectable E2A DNA binding and that DNA binding can be restored by culturing the cells in the presence of tamoxifen (9). E47R-reconstituted pre-B cells were treated with tamoxifen, and Ig
germ line transcript levels were examined by RT-PCR. Tamoxifen induced
germ line transcription in E47R pre-B cells but had no effect on
transcript levels in wild-type or E2A/ cells (Fig. 2A). Next, we examined Ig
recombinase accessibility in E47R cells by LM-PCR and found that tamoxifen treatment caused the accumulation of J
1 signal ends, while mock treatment of E47R cells did not (Fig. 2B). Since these data show that E47R is sufficient to activate Ig
germ line transcription and promote J
recombinase accessibility, we then asked if E2A is required to maintain Ig
gene activation in pre-B cells. E47R pre-B cells were treated with tamoxifen for 6 h, washed, and cultured in the absence of tamoxifen. Increased
germ line transcription was observed upon removal of tamoxifen (t = 0) and was maintained for up to 24 h but by 48 h had declined to the level observed for mock-treated cells (Fig. 2C). These results demonstrate that E2A is necessary to activate and maintain Ig
germ line transcription and is involved in promoting recombinase accessibility of the J
genes in our pre-B-cell lines.
|
enhancer histone acetylation.
Since E2A has been implicated in mediating chromatin remodeling, we asked what effect E2A deficiency has on chromatin modification at the Ig
enhancers (5, 18). We purified mononucleosomes from E2A+/+ or E2A/ pre-B cells and performed IPs to enrich for acetylated H3 or H4 histones. The enrichment of DNA sequences associated with acetylated H3 or H4 at
Ei and
E3' was determined by quantitative real-time PCR. We examined Ig
enhancer acetylation for three E2A/ clones, one untreated and two treated with STI-571. We found that the H3 acetylation at
Ei was decreased in E2A/ pre-B cells (Fig. 3A). We also observed that in the presence of STI-571, H3 acetylation at
Ei was marginally lower in two independent E2A/ clones than in E2A+/+ cells. Reduced H3 acetylation was also observed to occur at
E3' in untreated E2A/ pre-B cells and in both E2A/ clones treated with STI-571 (Fig. 3A). H4 acetylation was also reduced at
Ei and
E3' in STI-571-treated E2A/ pre-B cells compared to the level in STI-571-treated E2A+/+ cells (Fig. 3B). These results indicate that E2A deficiency can perturb Ig
enhancer histone acetylation when the locus is activated but also show that the maintenance of H3 and H4 acetylation at
Ei and
E3' is not entirely dependent on E2A. The reduction in H3 and H4 acetylation we observed was specific to the Ig
enhancers, since enrichment of the housekeeping gene G6PD remained constant between all samples. We observed a consistent increase in H3 acetylation at
E3' and H4 acetylation at
Ei and
E3' upon STI-571 treatment of E2A+/+ pre-B cells. However, we did not observe this increase with the two E2A/ clones treated with STI-571, indicating that E2A is required to promote hyperacetylation of the Ig
enhancers after STI-571 treatment.
|
histone acetylation.
Since we observed that E47R promotes Ig
germ line transcription and recombinase accessibility, we asked if E47R could promote chromatin modification of Ig
. Tamoxifen-treated E47R cells show a moderate increase in histone H3 acetylation and a large increase in H4 acetylation at both
Ei and
E3' compared to levels for mock-treated E47R pre-B cells (Fig. 4). Therefore, E47R is capable of promoting Ig
enhancer histone acetylation in a manner that correlates with the induction of germ line transcription and recombinase accessibility. We also examined the two Ig
germ line promoters to determine if E47R activation could influence histone acetylation at these regulatory elements as well. The
o promoter, located approximately 3.5 kb upstream of J
1, showed a significant increase in H4 acetylation, while H3 acetylation decreased slightly in E47R cells treated with tamoxifen (Fig. 4). The J
1 promoter, located immediately upstream of the J
1 exon, also exhibited a significant increase in H4 acetylation and little change in H3 acetylation in response to tamoxifen treatment (Fig. 4). The increases in histone acetylation at the Ig
enhancers and promoters upon tamoxifen treatment was not due to a global increase in histone acetylation, since G6PD acetylation was slightly decreased in tamoxifen-treated E47R pre-B cells. These data demonstrate that increased H4 acetylation and to a lesser extent H3 acetylation may occur at the Ig
enhancers in a manner that is dependent on E47R activity.
|
enhancers upon STI-571 treatment.
We directly examined E2A association with the Ig
enhancers by E2A ChIP with an Ab-MuLV-transformed pre-B-cell line from a mouse carrying dual-affinity-tagged E2A (E2AFH) (10). E2A ChIP was performed on chromatin from E2AFH pre-B cells treated with or without STI-571 for 6 h, and the relative enrichment of sequences corresponding to
Ei and
E3' was determined by quantitative PCR. We observed significant enrichment of E2A at the Ig
enhancers in untreated cells and found that upon STI-571 treatment E2A association doubled at the 3' enhancer and increased approximately 70% at the intronic enhancer (Fig. 5A). This increase in E2A association was specific to the Ig
enhancers, since we observed no significant change in the enrichment of sequence corresponding to the Ig heavy chain intronic enhancer between STI-571-treated and untreated cells. We also consistently found that E2A association with
E3' was significantly greater than with
Ei.
|
E3' in vivo and regulates Ig
locus activation.
Since IRF-4 has been shown to promote E2A DNA binding at
E3' in vitro (22) and IRF-4 expression is induced upon STI-571 treatment (Fig. 1D), we speculated that the increased E2A association with
E3' observed after STI-571 treatment may be dependent on IRF-4. To test this hypothesis, we inhibited IRF-4 expression by stably transducing the E2AFH cell line with a nshRNAi IRF-4 knockdown construct (IRF-4KD). Quantitative RT-PCR revealed that the IRF-4 mRNA level was reduced approximately sixfold in the untreated E2AHF cell line (Fig. 5B). We observed that STI-571 treatment induced IRF-4 mRNA levels in both the parental and knockdown cell lines but that the absolute level of IRF-4 mRNA was approximately 60% lower in the knockdown cell line than in the parental cell line (Fig. 5B). Next, we asked if the STI-571-dependent increase in E2A association with
E3' could be inhibited in the E2AFH IRF-4KD cells. Since previously published works suggest that IRF-4 may influence E2A DNA binding at Ig heavy chain Eµ, we also analyzed the mb-1 promoter to provide an additional independent locus that is known to associate with E2A (10, 23). Quantitative PCR analysis of E2A ChIP DNA fragments from E2AFH IRF-4KD cells showed that E2A association with
E3' failed to increase after STI-571 treatment (Fig. 5C). E2A association with Ig heavy chain Eµ or the mb-1 promoter in the presence of STI-571 was only slightly decreased compared to results with untreated cells. Quantitative RT-PCR analysis of the cell lines verified that the failure to observe increased E2A association with
E3' in the IRF-4KD line was not due to a reduction in E2A gene expression (Fig. 5B). These data provide evidence indicating that IRF-4 can promote E2A association with
E3' in the context of the endogenous locus.
Next, we examined if IRF-4 knockdown had an effect on Ig
germ line transcription and chromatin modification. Two independent shRNAi IRF-4 knockdown constructs were stably expressed in an Ab-MuLV-transformed pre-B-cell line, and IRF-4 and Ig
transcript levels were determined by quantitative RT-PCR. The shRNAi constructs 6-D1 and 9-H4 suppressed IRF-4 mRNA levels 6-fold and 10-fold, respectively, in untreated cells (Fig. 6A). STI-571 treatment increased IRF-4 mRNA levels in the parental cell line and in clone 6-D1, but the absolute IRF-4 mRNA level in clone 6-D1 was still sevenfold lower than that of the parental cell line. We observed that Ig
transcript levels were also significantly reduced for both untreated and STI-571-treated IRF-4 knockdown cells (Fig. 6A). These data show that Ig
germ line transcription is dependent on the expression of IRF-4.
|
germ line transcription, we hypothesized that IRF-4 may play a role in regulating Ig
chromatin modification. IRF-4 knockdown clone 6D-1 was further analyzed to determine levels of H3 and H4 histone acetylation at
Ei and
E3'. Mononucleosomes were prepared from parental cells and IRF-4KD cells treated with or without STI-571, and acetylated H3 or acetylated H4 histones were immunoprecipitated. We found that knockdown of IRF-4 significantly reduced both H3 and H4 acetylation at both
enhancers (Fig. 6B). In addition, STI-571-mediated H3 and H4 hyperacetylation of
Ei and
E3' was significantly reduced in the IRF-4KD cell line. These results suggest that IRF-4 facilitates Ig
germ line transcription through a mechanism that involves promoting Ig
enhancer histone acetylation.
Regulation of the Ig
locus by E2A during normal pre-B-cell development.
Finally, we sought to understand how E2A regulates Ig
locus activation and germ line transcription during normal B-cell development. E2A heterozygous mice were crossed with mice carrying a
o-GFP knockin allele, in which
o germ line transcription is conveniently revealed by a green fluorescent protein (GFP) marker inserted into the J
1 exon (15). We first asked if a reduction in E2A gene dose has an effect on the rate of monoallelic Ig
germ line transcription in pre-B cells. Bone marrow from 2- to 3-month-old E2A+/+ Ig
+/G or E2A+/ Ig
+/G mice was isolated and examined for GFP expression in B220+ CD43low/ IgM small pre-B cells. We observed no significant difference in GFP mean fluorescence intensity with pre-B cells from E2A+/+ mice and pre-B cells from E2A+/ mice, suggesting that E2A expression level does not influence the rate of germ line transcription from an active
o-GFP allele (Fig. 7A).
|
o-GFP allele. We found that the total number of pre-B cells and immature B cells was reduced in E2A+/ mice (Fig. 7B). This result is consistent with previous studies showing that E2A heterozygous mice have a partial block in B-cell development and reduced numbers of pro-B cells and pre-B cells (2, 11, 27, 37). A closer examination of the pre-B-cell populations in E2A+/+ and E2A+/ mice revealed that there was a significantly greater proportion of GFP+ pre-B cells in E2A heterozygous mice (Fig. 7C). The percentage of GFP+ pre-B cells was 1.5% ± 0.2% (n = 12) in E2A+/+ mice and 2.6% ± 0.3% (n = 9) in E2A+/ mice. Interestingly, the total numbers of GFP+ pre-B cells per tibia in E2A+/+ (1.4 x 104 ± 0.17 x 104) mice and E2A+/ (1.4 x 104 ± 0.15 x 104) mice were equivalent. When we examined the immature-B-cell population of the bone marrow, we found that there was only a slight increase in the percentage of GFP+ cells in the E2A heterozygous mice. These results suggest that E2A gene dosage can influence the frequency of pre-B cells expressing
germ line transcripts during B-cell development in vivo. | DISCUSSION |
|---|
|
|
|---|
germ line transcription and recombination are regulated by multiple regulatory elements which include the intronic enhancer, 3' enhancer, and germ line promoters (4, 13, 35). E2A directly interacts with both of the kappa enhancers, but the importance of these interactions and the mechanism by which E2A regulates Ig
is only beginning to be rigorously explored (10). Our data demonstrate that E2A is absolutely required for facilitation of Ig
locus activation and recombination. E2A/ pre-B cells retain B-cell lineage identity and express the B-cell-specific transcription factors Pax-5 and EBF (9). Among the transcripts we examined, only PU.1 and SpiB expression levels were decreased in E2A/ cells treated with STI-571. However, it is unlikely that reduced expression of PU.1 and SpiB can account for the severe decrease in Ig
germ line transcription, since it has been demonstrated that PU.1//SpiB/ pro-B cells are capable of expressing Ig
germ line transcript (32). These results strongly indicate that the defect in Ig
transcription is due to the absence of E2A interactions with cis regulatory elements on the
locus rather than a defect in the expression of a secondary gene.
Interestingly, RAG expression was not perturbed in our E2A-deficient cell lines. Previous studies have shown that the RAG locus contains an enhancer, Erag, which is regulated in part by E2A and is required for optimal RAG expression in early B-cell progenitors (12). E2A binds to Erag and can activate transcription from an Erag-containing reporter construct. Although E2A regulates the RAG locus, similar levels of RAG transcript were observed with STI-571-treated E2A+/+ and E2A/ pre-B-cell lines. These results suggest that E2A may play a role in regulating Erag at an earlier stage of B-cell development or that E2A is not absolutely essential for the maintenance of RAG transcription once the locus is active. These data also show that the block in Ig
and Ig
recombination in our E2A/ pre-B-cell lines is not due to a deficiency in RAG expression.
It is known that E2A binds directly to the Ig
intronic enhancer (10, 21). The E-boxes, E1 and E2, located in the Ig
intronic enhancer have been shown to be essential for efficient
recombination in vivo (14). Evidence suggests that E2A may play a role in regulating Ig
chromatin structure, since E2A has been shown to interact directly with histone acetyl transferases and the SAGA chromatin remodeling complex (3, 18). Upon analysis of the intronic enhancer, we were surprised to find that histone acetylation was not dramatically altered by E2A gene status in untreated cells. Interestingly, we found that upon STI-571 treatment histone hyperacetylation of the Ig
3' enhancer was perturbed in the absence of E2A. This suggests that E2A may play a role in regulating
enhancer chromatin modification upon activation of the locus. While we show that maintenance of intronic enhancer acetylation is not entirely dependent on E2A, these results do not rule out the possibility that E2A is required to initiate chromatin modification of the Ig
enhancers at an earlier point in B-cell development. These results also raise the possibility that E2A regulates intronic enhancer function through a mechanism that may involve but is not entirely dependent on histone acetylation. The induction of
germ line transcription by STI-571 also correlates with a significant increase in histone acetylation at the 3' enhancer in E2A+/+ pre-B cells. E2A/ pre-B cells treated with STI-571 express little
germ line transcript and show no increase in 3' enhancer acetylation (Fig. 1D and 3A and B). These data suggest that E2A activity may be developmentally regulated at the 3' enhancer and that E2A plays an important role in regulating the activity of this enhancer.
Analysis of E47R-reconstituted pre-B cells revealed that E2A activity can promote histone acetylation of the Ig
enhancers. In addition, we also observed that H4 acetylation of the Ig
germ line promoters was increased by E47R. Sequence analysis of the
o and J
1 germ line promoters revealed that both contain potential E2A DNA binding sites, but we did not detect significant E2A association with either promoter by E2A ChIP (data not shown). Therefore, it is possible that the increase in H4 acetylation observed at the germ line promoters is an indirect consequence of E47R activity. We also noticed that the overall level of Ig
enhancer acetylation was significantly greater in E47R-reconstituted pre-B cells than in the parental E2A/ pre-B-cell line or E2A sufficient cells. In addition, uninduced E47R-reconstituted cells also exhibit a higher basal level of Ig
germ line transcript than E2A+/+ cells. Increased Ig
gene activity in E47R pre-B cells may be a result of quantitative differences in the level of retrovirally expressed E47R versus endogenous E2A expression. Furthermore, it is possible that E47R, which was created from the human E2A isoform E2-5 cDNA, may function at Ig
in a manner that is qualitatively different from the endogenous mouse E2A protein, thereby resulting in increased Ig
germ line transcription and enhancer acetylation. Nevertheless, E47R can complement E2A deficiency at Ig
and we observe that enhancer hyperacetylation correlates with increased
germ line transcription in E47R cells just as it does in E2A+/+ pre-B cells treated with STI-571.
Chromatin immunoprecipitation of E2A revealed that there is a significant increase in E2A association with the Ig
enhancers that correlates with Ig
locus activation. These data suggest that there may be a threshold of E2A association with Ig
that must be achieved in order to fully activate the locus. Such a mechanism may explain why tamoxifen activation of retrovirally expressed E47R or ectopic E2A expression in nonlymphoid cells alone is sufficient to activate Ig
(7, 29). Interestingly, we also found that there was a significantly stronger association of E2A with the 3' enhancer than with the intronic enhancer in our pre-B-cell lines. This suggests that E2A association with
E3' may be particularly important for
locus activation in pre-B cells.
It has been shown that IRF-4 directly binds to
E3' and is required for Ig
gene activation and recombination in pre-B cells (17). E2A recruitment to
E3' in pre-B cells correlates with the STI-571-induced increase in IRF-4 expression. Conversely, suppression of IRF-4 transcript by RNAi prevented increased E2A association with
E3'. These observations provide evidence that supports previous in vitro findings showing that IRF-4 promotes E2A DNA binding at
E3' (22). Our results also suggest that IRF-4 works in parallel with E2A at Ig
in pre-B cells, since the induction of IRF-4 transcription by STI-571 is not dependent on E2A and is not sufficient to rescue Ig
germ line transcription in E2A/ pre-B cells (Fig. 1D). Based on our findings, we propose that IRF-4 promotes the recruitment of E2A to
E3' in pre-B cells and that E2A/IRF-4 synergy at
E3' plays a critical role in driving
locus activation.
IRF-4 deficiency also impaired Ig
germ line transcription and enhancer histone acetylation. We found that IRF-4 deficiency has a greater impact on Ig
enhancer histone acetylation than E2A deficiency, suggesting that IRF-4 plays a broader role in regulating Ig
chromatin modification, possibly through its interaction with Pu.1. We also found that histone hyperacetylation of the intronic enhancer was decreased in IRF-4KD cells. Since IRF-4 does not directly bind to this enhancer, it is likely that more-distal IRF-4 DNA binding sites must influence the intronic enhancer. It has recently been shown that the
intronic and 3' enhancers can directly interact through DNA looping (16). It is possible that the disruption of IRF-4 associations at the 3' enhancer disrupts looping of the enhancers, thereby perturbing intronic enhancer histone acetylation and activation of the Ig
locus. Alternately, it is possible that IRF-4 is required for the expression of a factor that is required for
Ei histone acetylation. Further studies should help to clarify the mechanism by which IRF-4 influences
Ei chromatin modification.
Our analysis of
o-GFP mice revealed that the percentage of GFP+ pre-B cells in the bone marrow of E2A+/ Ig
+/G mice was greater than that for E2A wild-type mice. Previous studies have shown that the GFP+ pre-B cells are actively engaged in V-J recombination and are the precursors of immature B cells (15). Thus, the accumulation of GFP+ pre-B cells in E2A+/ mice may indicate that Ig
recombination is partially blocked or inefficient. An E2A-dependent reduction in Ig
recombination efficiency could result from reduced recombinase accessibility of the
locus or reduced RAG expression. BCR transgenic E2A heterozygous mice have been shown to have significantly lower RAG expression than their E2A wild-type counterparts (27). Impaired RAG expression in our E2A heterozygous mice could result in reduced light chain recombination efficiency. In addition, insufficient E2A expression may negatively impact kappa locus recombinase accessibility by perturbing chromatin modification of the locus. These two mechanisms are not mutually exclusive and may both contribute to the pre-B phenotype we observed with the E2A+/ Ig
+/G mice.
In light of our data on the interaction of E2A and IRF-4, it would be of great interest to further test genetic interaction between these two molecules. Such studies will provide valuable insight into the underlying mechanisms of Ig
regulation and shed light on how a broadly expressed transcription factor such as E2A can be specifically directed to regulate the activity of a lineage-restricted locus such as Ig
.
| ACKNOWLEDGMENTS |
|---|
This work was supported by National Institutes of Health grants CA072433 to Y. Zhuang and HL48702 and AI40227 to M. Schlissel.
We have no conflicting financial interests.
| FOOTNOTES |
|---|
| REFERENCES |
|---|
|
|
|---|
2. Bain, G., E. C. Maandag, D. J. Izon, D. Amsen, A. M. Kruisbeek, B. C. Weintraub, I. Krop, M. S. Schlissel, A. J. Feeney, M. van Roon, et al. 1994. E2A proteins are required for proper B cell development and initiation of immunoglobulin gene rearrangements. Cell 79:885-892.[CrossRef][Medline]
3. Bradney, C., M. Hjelmeland, Y. Komatsu, M. Yoshida, T. P. Yao, and Y. Zhuang. 2003. Regulation of E2A activities by histone acetyltransferases in B lymphocyte development. J. Biol. Chem. 278:2370-2376.
4. Cocea, L., A. De Smet, M. Saghatchian, S. Fillatreau, L. Ferradini, S. Schurmans, J.-C. Weill, and C.-A. Reynaud. 1999. A targeted deletion of a region upstream from the J
cluster impairs
chain rearrangement in cis in mice and in the 103/bcl2 cell line. J. Exp. Med. 189:1443-1450.
5. Eckner, R., T. P. Yao, E. Oldread, and D. M. Livingston. 1996. Interaction and functional collaboration of p300/CBP and bHLH proteins in muscle and B-cell differentiation. Genes Dev. 10:2478-2490.
6. Eisenbeis, C. F., H. Singh, and U. Storb. 1995. Pip, a novel IRF family member, is a lymphoid-specific, PU.1-dependent transcriptional activator. Genes Dev. 9:1377-1387.
7. Goebel, P., N. Janney, J. R. Valenzuela, W. J. Romanow, C. Murre, and A. J. Feeney. 2001. Localized gene-specific induction of accessibility to V(D)J recombination induced by E2A and early B cell factor in nonlymphoid cells. J. Exp. Med. 194:645-656.
8. Gorman, J. R., N. van der Stoep, R. Monroe, M. Cogne, L. Davidson, and F. W. Alt. 1996. The Ig(kappa) enhancer influences the ratio of Ig(kappa) versus Ig(lambda) B lymphocytes. Immunity 5:241-252.[CrossRef][Medline]
9. Greenbaum, S., A. S. Lazorchak, and Y. Zhuang. 2004. Differential functions for the transcription factor E2A in positive and negative gene regulation in pre-B lymphocytes. J. Biol. Chem. 279:45028-45035.
10. Greenbaum, S., and Y. Zhuang. 2002. Identification of E2A target genes in B lymphocyte development by using a gene tagging-based chromatin immunoprecipitation system. Proc. Natl. Acad. Sci. USA 99:15030-15035.
11. Herblot, S., P. D. Aplan, and T. Hoang. 2002. Gradient of E2A activity in B-cell development. Mol. Cell. Biol. 22:886-900.
12. Hsu, L. Y., J. Lauring, H. E. Liang, S. Greenbaum, D. Cado, Y. Zhuang, and M. S. Schlissel. 2003. A conserved transcriptional enhancer regulates RAG gene expression in developing B cells. Immunity 19:105-117.[CrossRef][Medline]
13. Inlay, M., F. W. Alt, D. Baltimore, and Y. Xu. 2002. Essential roles of the kappa light chain intronic enhancer and 3' enhancer in kappa rearrangement and demethylation. Nat. Immunol. 3:463-468.[CrossRef][Medline]
14. Inlay, M. A., H. Tian, T. Lin, and Y. Xu. 2004. Important roles for E protein binding sites within the immunoglobulin kappa chain intronic enhancer in activating Vkappa Jkappa rearrangement. J. Exp. Med. 200:1205-1211.
15. Liang, H. E., L. Y. Hsu, D. Cado, and M. S. Schlissel. 2004. Variegated transcriptional activation of the immunoglobulin kappa locus in pre-b cells contributes to the allelic exclusion of light-chain expression. Cell 118:19-29.[CrossRef][Medline]
16. Liu, Z., and W. T. Garrard. 2005. Long-range interactions between three transcriptional enhancers, active V
gene promoters, and a 3' boundary sequence spanning 46 kilobases. Mol. Cell. Biol. 25:3220-3231.
17. Lu, R., K. L. Medina, D. W. Lancki, and H. Singh. 2003. IRF-4,8 orchestrate the pre-B-to-B transition in lymphocyte development. Genes Dev. 17:1703-1708.
18. Massari, M. E., P. A. Grant, M. G. Pray-Grant, S. L. Berger, J. L. Workman, and C. Murre. 1999. A conserved motif present in a class of helix-loop-helix proteins activates transcription by direct recruitment of the SAGA complex. Mol. Cell 4:63-73.[CrossRef][Medline]
19. McMurry, M. T., and M. S. Krangel. 2000. A role for histone acetylation in the developmental regulation of VDJ recombination. Science 287:495-498.
20. Muljo, S. A., and M. S. Schlissel. 2003. A small molecule Abl kinase inhibitor induces differentiation of Abelson virus-transformed pre-B cell lines. Nat. Immunol. 4:31-37.[CrossRef][Medline]
21. Murre, C., P. S. McCaw, and D. Baltimore. 1989. A new DNA binding and dimerization motif in immunoglobulin enhancer binding, daughterless, MyoD, and myc proteins. Cell 56:777-783.[CrossRef][Medline]
22. Nagulapalli, S., and M. L. Atchison. 1998. Transcription factor Pip can enhance DNA binding by E47, leading to transcriptional synergy involving multiple protein domains. Mol. Cell. Biol. 18:4639-4650.
23. Nagulapalli, S., A. Goheer, L. Pitt, L. P. McIntosh, and M. L. Atchison. 2002. Mechanism of e47-Pip interaction on DNA resulting in transcriptional synergy and activation of immunoglobulin germ line sterile transcripts. Mol. Cell. Biol. 22:7337-7350.
24. Pan, L., J. Hanrahan, J. Li, L. P. Hale, and Y. Zhuang. 2002. An analysis of T cell intrinsic roles of E2A by conditional gene disruption in the thymus. J. Immunol. 168:3923-3932.
25. Pongubala, J. M. R., and M. L. Atchison. 1991. Functional characterization of the developmentally controlled immunoglobulin kappa 3' enhancer: regulation by Id, a repressor of helix-loop-helix transcription factors. Mol. Cell. Biol. 11:1040-1047.
26. Pongubala, J. M. R., S. Nagulapalli, M. J. Klemsz, S. R. McKercher, R. A. Maki, and M. L. Atchison. 1992. PU.1 recruits a second nuclear factor to a site important for immunoglobulin
3' enhancer activity. Mol. Cell. Biol. 12:368-378.
27. Quong, M. W., A. Martensson, A. W. Langerak, R. R. Rivera, D. Nemazee, and C. Murre. 2004. Receptor editing and marginal zone B cell development are regulated by the helix-loop-helix protein, E2A. J. Exp. Med. 199:1101-1112.
28. Rolink, A., M. Streb, and F. Melchers. 1991. The kappa/lambda ratio in surface immunoglobulin molecules on B lymphocytes differentiating from DHJH-rearranged murine pre-B cell clones in vitro. Eur. J. Immunol. 21:2895-2898.[Medline]
29. Romanow, W. J., A. W. Langerak, P. Goebel, I. L. Wolvers-Tettero, J. J. van Dongen, A. J. Feeney, and C. Murre. 2000. E2A and EBF act in synergy with the V(D)J recombinase to generate a diverse immunoglobulin repertoire in nonlymphoid cells. Mol. Cell 5:343-353.[CrossRef][Medline]
30. Schlissel, M. S. 2004. Regulation of activation and recombination of the murine Igkappa locus. Immunol. Rev. 200:215-223.[CrossRef][Medline]
31. Schlissel, M. S., and D. Baltimore. 1989. Activation of immunoglobulin kappa gene rearrangement correlates with induction of germline kappa gene transcription. Cell 58:1001-1007.[CrossRef][Medline]
32. Schweitzer, B. L., and R. P. DeKoter. 2004. Analysis of gene expression and Ig transcription in PU.1/Spi-B-deficient progenitor B cell lines. J. Immunol. 172:144-154.
33. Shaffer, A. L., A. Peng, and M. S. Schlissel. 1997. In vivo occupancy of the kappa light chain enhancers in primary pro- and pre-B cells: a model for kappa locus activation. Immunity 6:131-143.[CrossRef][Medline]
34. Van Ness, B. G., M. Weigert, C. Coleclough, E. L. Mather, D. E. Kelley, and R. P. Perry. 1981. Transcription of the unrearranged mouse C kappa locus: sequence of the initiation region and comparison of activity with a rearranged V kappa-C kappa gene. Cell 27:593-602.[CrossRef][Medline]
35. Xu, Y., L. Davidson, F. W. Alt, and D. Baltimore. 1996. Deletion of the Ig kappa light chain intronic enhancer/matrix attachment region impairs but does not abolish V kappa J kappa rearrangement. Immunity 4:377-385.[CrossRef][Medline]
36. Zhuang, Y., A. Jackson, L. Pan, K. Shen, and M. Dai. 2004. Regulation of E2A gene expression in B-lymphocyte development. Mol. Immunol. 40:1165-1177.[CrossRef][Medline]
37. Zhuang, Y., P. Soriano, and H. Weintraub. 1994. The helix-loop-helix gene E2A is required for B cell formation. Cell 79:875-884.[CrossRef][Medline]
This article has been cited by other articles: